Loading company…
Medimscience develops tumor immunotherapy drugs and provides antibody research services.
Medimscience develops drugs targeting macrophages in the tumor immune microenvironment. It also offers protein customization and monoclonal antibody screening services. Founded in 2019 and based in Hangzhou, China, it raised over CNY 150 million in Series A funding in April 2026.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in